ArticleTobacco induced diseases2025
Trends, differences, and future projections of lung cancer attributable to secondhand smoke across 204 countries and territories from 1990 to 2036.
Article in Tobacco induced diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Evaluating the DALY impact of disease associated with second-hand smoke exposure in different socio-demographic index regions.Substance abuse treatment, prevention, and policy · 2026Article
- Review
- Trends and projections of smoking-attributable lung cancer burden among the elderly in China, 1990-2021.American journal of cancer research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSecondhand smoke (SHS) has long been identified as a significant risk factor for lung cancer, yet the precise magnitude of its contribution to the global lung cancer burden remains unclear. Our study aims to elucidate the harms associated with lung cancer caused by secondhand smoke while emphasizing the importance of avoiding SHS.
methodsThe annual deaths and disability-adjusted life years (DALYs) data were obtained from the Global Burden of Disease Study (GBD) 2021 for this secondary dataset analysis. Trends in mortality and DALYs were evaluated, along with correlations with the sociodemographic index (SDI). Projections from 2021 to 2036 utilized a Bayesian age-period-cohort model.
resultsIn 1990, SHS-related lung cancer was responsible for approximately 0.058 million deaths and 1.599 million DALYs, globally. By 2021, these numbers had increased to approximately 0.098 million deaths and 2.356 million DALYs worldwide. Between 1990 and 2021, SHS-related lung cumulatively caused 2.428 million deaths and 62.785 million DALYs. From 1990 to 2021, deaths and DALYs increased significantly, while age-standardized mortality rates (ASMR) and age-standardized DALY rates (ASDR) decreased. Specifically, ASMR decreased from 1.45 to 1.14, and ASDR dropped from 38.40 to 26.93. The high-middle SDI region bore the largest burden, accounting for nearly 40% of global deaths and DALYs. East Asia held the highest burden of lung cancer attributable to secondhand smoke in 2021, while Oceania had the lowest burden. Projections suggest that male ASMR will decline to 1.18 by 2036, while female ASMR is expected to rise to 0.91 by 2029 before decreasing to 0.89 by 2036.
conclusionsThe considerable burden of lung cancer attributable to secondhand smoke underscores the urgent need for targeted public health interventions, particularly in high-risk demographics and regions. To mitigate disparities and enhance global health outcomes, it is crucial to prioritize the avoidance of SHS and the establishment of smoke-free environments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.